Lung Cancer
7 competing products in clinical development for Lung Cancer.
Pipeline by Phase
Pre-clinical1
Phase 11
Phase 22
Phase 33
All Products (7)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Nivolumab + Topotecan + Amrubicin | Ono Pharmaceutical | Phase 3 | Completed | 40 |
| Nivolumab + Ipilimumab | Ono Pharmaceutical | Phase 3 | Completed | 40 |
| soblidotin | Daiichi Sankyo | Phase 2 | Completed | 35 |
| YM155 | Astellas Pharma | Phase 2 | Completed | 35 |
| Patritumab + Erlotinib + Placebo | Daiichi Sankyo | Phase 3 | Terminated | 32 |
| S-488210 + S-488211 | Shionogi | Phase 1 | Completed | 29 |
| Lazertinib 240 mg | Yuhan | Pre-clinical | Completed | 26 |